Pulmonx (LUNG) Competitors $1.84 +0.15 (+8.88%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.78 -0.06 (-2.99%) As of 10/3/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LUNG vs. SMTI, BWAY, OM, SKIN, CATX, SI, MGRM, TLSI, INGN, and NNOXShould you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include Sanara MedTech (SMTI), Brainsway (BWAY), Outset Medical (OM), Beauty Health (SKIN), Perspective Therapeutics (CATX), Shoulder Innovations (SI), Monogram Orthopaedics (MGRM), TriSalus Life Sciences (TLSI), Inogen (INGN), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry. Pulmonx vs. Its Competitors Sanara MedTech Brainsway Outset Medical Beauty Health Perspective Therapeutics Shoulder Innovations Monogram Orthopaedics TriSalus Life Sciences Inogen Nano-X Imaging Pulmonx (NASDAQ:LUNG) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation. Do analysts prefer LUNG or SMTI? Pulmonx currently has a consensus target price of $7.66, indicating a potential upside of 316.54%. Sanara MedTech has a consensus target price of $50.00, indicating a potential upside of 60.31%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmonx 1 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.40Sanara MedTech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to LUNG or SMTI? In the previous week, Pulmonx and Pulmonx both had 1 articles in the media. Pulmonx's average media sentiment score of 0.05 beat Sanara MedTech's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in LUNG or SMTI? 91.0% of Pulmonx shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 42.6% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, LUNG or SMTI? Pulmonx has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Which has preferable earnings and valuation, LUNG or SMTI? Sanara MedTech has higher revenue and earnings than Pulmonx. Sanara MedTech is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmonx$83.79M0.89-$56.39M-$1.43-1.29Sanara MedTech$86.67M3.20-$9.66M-$1.16-26.89 Is LUNG or SMTI more profitable? Sanara MedTech has a net margin of -10.22% compared to Pulmonx's net margin of -62.88%. Sanara MedTech's return on equity of -26.43% beat Pulmonx's return on equity.Company Net Margins Return on Equity Return on Assets Pulmonx-62.88% -69.76% -36.26% Sanara MedTech -10.22%-26.43%-10.69% SummarySanara MedTech beats Pulmonx on 9 of the 15 factors compared between the two stocks. Get Pulmonx News Delivered to You Automatically Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUNG vs. The Competition Export to ExcelMetricPulmonxMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.98M$2.28B$6.12B$10.56BDividend YieldN/AN/A5.66%4.70%P/E Ratio-1.2939.3386.9626.71Price / Sales0.8945.67588.14233.84Price / CashN/A60.2026.3031.09Price / Book0.8512.5612.536.57Net Income-$56.39M-$64.84M$3.30B$276.78M7 Day Performance11.52%3.08%3.53%1.98%1 Month Performance5.75%6.33%6.77%9.13%1 Year Performance-74.79%34.71%70.60%31.60% Pulmonx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUNGPulmonx3.3386 of 5 stars$1.84+8.9%$7.66+316.5%-74.8%$74.98M$83.79M-1.29250Positive NewsAnalyst DowngradeSMTISanara MedTech1.9494 of 5 stars$31.840.0%$50.00+57.0%+6.2%$283.54M$86.67M-27.4560Positive NewsBWAYBrainsway2.9285 of 5 stars$15.29+4.3%$18.00+17.7%+61.2%$278.14M$41.02M58.81120OMOutset Medical1.4362 of 5 stars$14.49-0.2%$24.67+70.2%+55.6%$257.96M$113.69M-0.71520SKINBeauty Health2.2319 of 5 stars$2.00+1.5%$2.81+40.6%+13.5%$249.85M$334.30M-7.141,030Positive NewsGap UpCATXPerspective Therapeutics2.1586 of 5 stars$3.35-1.5%$12.56+274.8%-72.7%$248.78MN/A0.0070News CoverageAnalyst ForecastSIShoulder Innovations2.8214 of 5 stars$12.55+3.7%$19.60+56.2%N/A$246.36MN/A-0.4261MGRMMonogram Orthopaedics1.1207 of 5 stars$5.95+0.7%$5.40-9.2%+163.4%$240.14M$370K-11.9028Positive NewsHigh Trading VolumeTLSITriSalus Life Sciences2.1661 of 5 stars$4.67-0.6%$10.90+133.4%+1.5%$234.38M$29.43M-3.96106INGNInogen3.9996 of 5 stars$8.11-1.3%$11.00+35.6%-5.2%$222.27M$335.70M-7.651,030NNOXNano-X Imaging2.1333 of 5 stars$3.75+0.8%$8.50+126.7%-38.1%$214.94M$11.28M-4.17190 Related Companies and Tools Related Companies Sanara MedTech Competitors Brainsway Competitors Outset Medical Competitors Beauty Health Competitors Perspective Therapeutics Competitors Shoulder Innovations Competitors Monogram Orthopaedics Competitors TriSalus Life Sciences Competitors Inogen Competitors Nano-X Imaging Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LUNG) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
